236 related articles for article (PubMed ID: 17043624)
1. Practical aspects of peptide receptor radionuclide therapy with [177Lu][DOTA0, Tyr3]octreotate.
Bakker WH; Breeman WA; Kwekkeboom DJ; De Jong LC; Krenning EP
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):265-71. PubMed ID: 17043624
[TBL] [Abstract][Full Text] [Related]
2. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients.
Kwekkeboom DJ; Bakker WH; Kooij PP; Konijnenberg MW; Srinivasan A; Erion JL; Schmidt MA; Bugaj JL; de Jong M; Krenning EP
Eur J Nucl Med; 2001 Sep; 28(9):1319-25. PubMed ID: 11585290
[TBL] [Abstract][Full Text] [Related]
3. On the preparation of a therapeutic dose of 177Lu-labeled DOTA-TATE using indigenously produced 177Lu in medium flux reactor.
Das T; Chakraborty S; Banerjee S; Venkatesh M
Appl Radiat Isot; 2007 Mar; 65(3):301-8. PubMed ID: 17110119
[TBL] [Abstract][Full Text] [Related]
4. Comparison of [177Lu-DOTA0,Tyr3]-octreotate and [177Lu-DOTA0,Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1.
Swärd C; Bernhardt P; Johanson V; Schmitt A; Ahlman H; Stridsberg M; Forssell-Aronsson E; Nilsson O; Kölby L
Cancer Biother Radiopharm; 2008 Feb; 23(1):114-20. PubMed ID: 18298335
[TBL] [Abstract][Full Text] [Related]
5. Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitro.
Capello A; Krenning EP; Breeman WA; Bernard BF; Konijnenberg MW; de Jong M
Cancer Biother Radiopharm; 2003 Oct; 18(5):761-8. PubMed ID: 14629824
[TBL] [Abstract][Full Text] [Related]
6. Radiation protection in 90Y-labelled DOTA-D-Phe1-Tyr3-octreotide preparations.
Grassi E; Sghedoni R; Asti M; Fioroni F; Salvo D; Borasi G
Nucl Med Commun; 2009 Feb; 30(2):176-82. PubMed ID: 19194215
[TBL] [Abstract][Full Text] [Related]
7. Finger doses for staff handling radiopharmaceuticals in nuclear medicine.
Pant GS; Sharma SK; Rath GK
J Nucl Med Technol; 2006 Sep; 34(3):169-73. PubMed ID: 16951286
[TBL] [Abstract][Full Text] [Related]
8. Early prediction of tumour response to PRRT. The sequential change of tumour-absorbed doses during treatment with 177Lu-octreotate.
Ezziddin S; Reichmann K; Yong-Hing C; Damm M; Risse J; Ahmadzadehfar H; Logvinski T; Guhlke S; Biersack HJ; Sabet A
Nuklearmedizin; 2013; 52(5):170-7. PubMed ID: 23963021
[TBL] [Abstract][Full Text] [Related]
9. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.
Helisch A; Förster GJ; Reber H; Buchholz HG; Arnold R; Göke B; Weber MM; Wiedenmann B; Pauwels S; Haus U; Bouterfa H; Bartenstein P
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1386-92. PubMed ID: 15175836
[TBL] [Abstract][Full Text] [Related]
10. In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy.
Chan HS; de Blois E; Morgenstern A; Bruchertseifer F; de Jong M; Breeman W; Konijnenberg M
PLoS One; 2017; 12(7):e0181473. PubMed ID: 28732021
[TBL] [Abstract][Full Text] [Related]
11. 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy.
Garkavij M; Nickel M; Sjögreen-Gleisner K; Ljungberg M; Ohlsson T; Wingårdh K; Strand SE; Tennvall J
Cancer; 2010 Feb; 116(4 Suppl):1084-92. PubMed ID: 20127957
[TBL] [Abstract][Full Text] [Related]
12. Radiation therapy of small cell lung cancer with 177Lu-DOTA-Tyr3-octreotate in an animal model.
Schmitt A; Bernhardt P; Nilsson O; Ahlman H; Kölby L; Maecke HR; Forssell-Aronsson E
J Nucl Med; 2004 Sep; 45(9):1542-8. PubMed ID: 15347722
[TBL] [Abstract][Full Text] [Related]
13. Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate.
Rolleman EJ; Forrer F; Bernard B; Bijster M; Vermeij M; Valkema R; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2007 May; 34(5):763-771. PubMed ID: 17146655
[TBL] [Abstract][Full Text] [Related]
14. Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0,Tyr3]octreotate therapy.
Melis M; Forrer F; Capello A; Bijster M; Bernard BF; Reubi JC; Krenning EP; De Jong M
Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):324-33. PubMed ID: 17923824
[TBL] [Abstract][Full Text] [Related]
15. Multidisciplinary approach including receptor radionuclide therapy with 90Y-DOTATOC ([90Y-DOTA0, Tyr3]-octreotide) and 177Lu-DOTATATE ([177Lu-DOTA0, Tyr3]-octreotate) in ectopic cushing syndrome from a metastatic gastrinoma: a promising proposal.
Davì MV; Bodei L; Ferdeghini M; Falconi M; Testoni M; Paganelli G; Oliani C; Lo Cascio V; Francia G
Endocr Pract; 2008 Mar; 14(2):213-8. PubMed ID: 18308661
[TBL] [Abstract][Full Text] [Related]
16. Extraventricular neurocytoma treated with 177Lu DOTATATE PRRT induction and maintenance therapies.
Makis W; McCann K; McEwan AJ
Clin Nucl Med; 2015 Mar; 40(3):234-6. PubMed ID: 25608145
[TBL] [Abstract][Full Text] [Related]
17. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma.
van Essen M; Krenning EP; Kooij PP; Bakker WH; Feelders RA; de Herder WW; Wolbers JG; Kwekkeboom DJ
J Nucl Med; 2006 Oct; 47(10):1599-606. PubMed ID: 17015894
[TBL] [Abstract][Full Text] [Related]
18. Molecular imaging of reduced renal uptake of radiolabelled [DOTA0,Tyr3]octreotate by the combination of lysine and Gelofusine in rats.
Rolleman EJ; Bernard BF; Breeman WA; Forrer F; de Blois E; Hoppin J; Gotthardt M; Boerman OC; Krenning EP; de Jong M
Nuklearmedizin; 2008; 47(3):110-5. PubMed ID: 18493690
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive dose reconstruction methodology for former rocketdyne/atomics international radiation workers.
Boice JD; Leggett RW; Ellis ED; Wallace PW; Mumma M; Cohen SS; Brill AB; Chadda B; Boecker BB; Yoder RC; Eckerman KF
Health Phys; 2006 May; 90(5):409-30. PubMed ID: 16607174
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]